What is the nature of the $19 million IPR&D charge for Q4 2025?

The $19 million IPR&D charge is an acquired in-process research and development expense incurred in the fourth quarter of 2025. This charge relates to investments in early-stage development projects acquired through asset acquisitions or related to collaboration and licensing agreements. It is expected to negatively impact both GAAP and non-GAAP earnings per diluted share by approximately $0.14 for the quarter.

What is the purpose of the $60 million charge related to the Good Days program?

The $60 million charge is a selling, general, and administrative expense incurred in Q4 2025 as part of Regeneron's commitment to a matching program for donations to Good Days, an independent non-profit organization focused on retinal vascular and neovascular diseases. Regeneron matched $60 million in donations received by the Fund for this initiative, up to a total committed amount.

Are the financial figures provided in the 8-K final?

No, the financial results discussed in this 8-K filing are preliminary and unaudited. They are subject to Regeneron's standard financial statement closing procedures, and there can be no assurance that the actual results will not differ from these estimates.

Where can investors find more detailed information about Regeneron's financial performance?

The 8-K filing incorporates by reference a presentation dated January 12, 2026, delivered at the 44th Annual J.P. Morgan Healthcare Conference (Exhibit 99.1), which contains the preliminary financial information. Investors should refer to this presentation and Regeneron's other SEC filings for more comprehensive details.

REGN 8-K: Earnings & Results & Regulation FD

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on January 12, 2026, providing a corporate update and preliminary unaudited financial information for the fourth quarter and full year 2025. The update, delivered at the J.P. Morgan Healthcare Conference, highlighted two key financial items: an anticipated acquired in-process research and development (IPR&D) charge of approximately $19 million, expected to reduce Q4 2025 diluted earnings per share by roughly $0.14 on both a GAAP and non-GAAP basis. This charge reflects investments in early-stage development projects. Additionally, the company reported a $60 million charge to selling, general, and administrative expenses in Q4 2025 related to its matching program for donations to Good Days, a non-profit supporting retinal disease research. Regeneron matched the $60 million in donations received by the Fund for this initiative.

Key Highlights

1Regeneron provided a corporate update at the 44th Annual J.P. Morgan Healthcare Conference.
2Preliminary, unaudited financial information for Q4 and full year 2025 was presented.
3An acquired IPR&D charge of approximately $19 million (pre-tax) is expected for Q4 2025.
4This IPR&D charge is estimated to reduce Q4 2025 diluted EPS by approximately $0.14 (GAAP and non-GAAP).
5A $60 million charge to SG&A was recorded in Q4 2025 for the Good Days donation matching program.
6The company highlighted its commitment to supporting retinal disease research through the Good Days initiative.
7All provided financial figures are preliminary and subject to finalization of financial closing procedures.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 12, 2026)

Summary

Key Highlights

Frequently Asked Questions